Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
6(46%)
Results Posted
33%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
4
31%
Ph phase_3
1
8%
Ph not_applicable
1
8%
Ph phase_1
3
23%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

6

trials recruiting

Total Trials

13

all time

Status Distribution
Active(6)
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Completed3
Recruiting3
Active, not recruiting3
unknown2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
6
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 31 (11.1%)
N/A1 (11.1%)

Trials by Status

unknown215%
completed323%
recruiting323%
active_not_recruiting323%
withdrawn18%
terminated18%

Recent Activity

6 active trials
Showing 5 of 13
completed

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

NCT04727723
active_not_recruitingphase_2

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

NCT03971461
recruitingphase_2

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

NCT04954820
active_not_recruitingphase_3

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
terminatedphase_2

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

NCT05987176
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04727723

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Completed
NCT03971461Phase 2

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Active Not Recruiting
NCT04954820Phase 2

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

Recruiting
NCT03972488Phase 3

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Active Not Recruiting
NCT05987176Phase 2

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Terminated
NCT03691064

Post-Authorization Long-Term Safety Study of LUTATHERA

Active Not Recruiting
NCT05844332

LUTATHERA Injection General Use Result Survey

Completed
NCT05178693Phase 1

Lutathera and ASTX727 in Neuroendocrine Tumours

Recruiting
NCT04609592Phase 1

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Recruiting
NCT04946305

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Completed
NCT04614766Phase 1

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Withdrawn
NCT05513469Not Applicable

Biomarker Identification of Radionuclide Therapy-induced Radiation Responses

Unknown
NCT04039516Phase 2

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13